DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025.
MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
For MannKind:
Investor Relations
Ana Kapor
(818) 661-5000
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations
Christie Iacangelo
(818) 292-3500
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.00 |
| Daily Change: | -0.06 -1.19 |
| Daily Volume: | 2,978,286 |
| Market Cap: | US$1.540B |
November 11, 2025 November 10, 2025 November 05, 2025 October 07, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
